Pharsight

1. List of Ingrezza drug patents

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Apr, 2031 (7 years from now)
US10065952	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10844058	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10851103	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10851104	NEUROCRINE	Valbenazine salts and polymorphs thereof	Oct, 2036 (13 years from now)
US10919892	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10906903	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
US10906902	NEUROCRINE	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)	Dec, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697	NEUROCRINE	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto	Nov, 2027 (4 years from now)
US11040029	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10912771	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10993941	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10857148	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10874648	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10857137	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US10952997	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Oct, 2037 (14 years from now)
US11026939	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (15 years from now)
US11311532	NEUROCRINE	High dosage valbenazine formulation and compositions, methods, and kits related thereto	Sep, 2038 (15 years from now)
US11026931	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2039 (16 years from now)
US10940141	NEUROCRINE	Methods for the administration of certain VMAT2 inhibitors	Aug, 2040 (17 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 11, 2022

NCE-1 date: 2021-04-11

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Method of administering valbenazine while avoiding concomitant use of ...

Dosage: CAPSULE;ORAL